Dédée F. Murrell

19.7k total citations · 1 hit paper
379 papers, 8.9k citations indexed

About

Dédée F. Murrell is a scholar working on Pathology and Forensic Medicine, Cell Biology and Rheumatology. According to data from OpenAlex, Dédée F. Murrell has authored 379 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 226 papers in Pathology and Forensic Medicine, 120 papers in Cell Biology and 103 papers in Rheumatology. Recurrent topics in Dédée F. Murrell's work include Autoimmune Bullous Skin Diseases (220 papers), Skin and Cellular Biology Research (113 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (95 papers). Dédée F. Murrell is often cited by papers focused on Autoimmune Bullous Skin Diseases (220 papers), Skin and Cellular Biology Research (113 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (95 papers). Dédée F. Murrell collaborates with scholars based in Australia, United States and Germany. Dédée F. Murrell's co-authors include John W. Frew, Linda K. Martin, Lizbeth R.A. Intong, Victoria P. Werth, Benjamin S. Daniel, Ningning Dang, Lynda Spelman, Cathy Zhao, Supriya S. Venugopal and Gudula Kirtschig and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Dédée F. Murrell

359 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB

2008 598 citations Jo‐David Fine, John A. McGrath et al. profile →

Peers

Countries citing papers authored by Dédée F. Murrell

Since Specialization

Citations

This map shows the geographic impact of Dédée F. Murrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dédée F. Murrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dédée F. Murrell more than expected).

Fields of papers citing papers by Dédée F. Murrell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dédée F. Murrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dédée F. Murrell. The network helps show where Dédée F. Murrell may publish in the future.

Co-authorship network of co-authors of Dédée F. Murrell

This figure shows the co-authorship network connecting the top 25 collaborators of Dédée F. Murrell. A scholar is included among the top collaborators of Dédée F. Murrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dédée F. Murrell. Dédée F. Murrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the phase III EASE study 2025 ·British Journal of Dermatology ·Dédée F. Murrell, (unknown), Anna L. Bruckner, (unknown), Charles S. Davis, (unknown), Dimitra Kiritsi, (unknown), Eli Sprecher, (unknown), Johannes S. Kern	3
2	Pilot Study of Tildrakizumab in the Treatment of Stable Non‐Segmental Vitiligo 2025 ·JEADV Clinical Practice ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Hossein Akbarialiabad, (unknown), (unknown), (unknown), Dédée F. Murrell, Benjamin S. Daniel	0
3	Effectiveness of Biologic Therapy in Hidradenitis Suppurativa: Real‐World Clinical Outcomes and Lipid Profile Evaluation 2025 ·Australasian Journal of Dermatology ·(unknown), (unknown), (unknown), Michael Stark, Mario Valenti, Alessandra Narcisi, (unknown), Dédée F. Murrell	0
4	The potential of Bruton’s tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease 2024 ·Expert Opinion on Pharmacotherapy ·(unknown), Dédée F. Murrell	2
5	Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy 2024 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), (unknown), Soner Uzun, Aslı Bilgiç Temel, (unknown), Baoqi Yang, Maryam Daneshpazhooh, (unknown), Aikaterini Patsatsi, (unknown), Hayato Takahashi, (unknown), (unknown), (unknown), Donna A. Culton, (unknown), (unknown), Boaz Shulruf, John H. Stone, Dédée F. Murrell	0
6	Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study 2023 ·Dermatology and Therapy ·Kalyani Marathe, Joyce Teng, Scott Guenthner, Christopher G. Bunick, Steven Kempers, (unknown), Leslie Castelo‐Soccio, Alan M. Mendelsohn, (unknown), Dédée F. Murrell	2
7	A Review of the Scoring and Assessment of Keratosis Pilaris 2023 ·Skin Appendage Disorders ·(unknown), (unknown), Dédée F. Murrell	1
8	From the Cochrane Library: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus 2023 ·JMIR Dermatology ·(unknown), (unknown), Dédée F. Murrell, Robert P. Dellavalle	1
9	Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience 2023 ·Clinical and Experimental Dermatology ·(unknown), (unknown), (unknown), (unknown), (unknown), Dédée F. Murrell	3
10	A review of JAK and IL‐23 inhibitors to treat vitiligo 2023 ·Australasian Journal of Dermatology ·(unknown), (unknown), Benjamin S. Daniel, Dédée F. Murrell	6
11	Allergic contact dermatitis to miconazole for nipple candidiasis 2022 ·Contact Dermatitis ·(unknown), Dédée F. Murrell, (unknown)	0
12	Over‐expression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas 2021 ·Experimental Dermatology ·(unknown), Chao Lyu, David T. Woodley, Dédée F. Murrell, Minhee Kim, Edel A. O’Toole, (unknown), Jon Cogan, (unknown), Ashley Wysong, Mei Chen	12
13	Assessing the quality of life in the families of patients with epidermolysis bullosa: The mothers as main caregivers 2021 ·International Journal of Women’s Dermatology ·(unknown), Mohammad Mahdi Parvizi, Dédée F. Murrell, Farhad Handjani	12
14	Impact of COVID‐19 on inpatient dermatology consults in an Australian tertiary hospital 2021 ·Australasian Journal of Dermatology ·(unknown), (unknown), (unknown), Benjamin S. Daniel, Dédée F. Murrell	2
15	Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN‐473) in the treatment of canine pemphigus foliaceus 2020 ·Veterinary Dermatology ·(unknown), (unknown), Catherine A. Outerbridge, Petra Bizikova, Dori L. Borjesson, Dédée F. Murrell, Angelina Bisconte, Michelle Francesco, Ronald J. Hill, Mohammad R. Masjedizadeh, Philip A. Nunn, Steven G. Gourlay, Stephen D. White	20
16	Sensitivity to change and correlation between the autoimmune bullous disease quality‐of‐life questionnaires ABQOL and TABQOL , and objective severity scores 2020 ·British Journal of Dermatology ·(unknown), André Gillibert, S. Duvert‐Lehembre, (unknown), M. Alexandre, C. Prost‐Squarcioni, F. Caux, E. Delaporte, N. Litrowski, C. Boulard, Dédée F. Murrell, P. Joly, V. Hébert	8
17	Successful dapsone therapy in inherited epidermolysis bullosa 2020 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), (unknown), Dédée F. Murrell	4
18	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement 2017 ·British Journal of Dermatology ·Aaron M. Drucker, Kilian Eyerich, Marjolein de Bruin‐Weller, Jacob P. Thyssen, Phyllis I. Spuls, Alan D. Irvine, Giampiero Girolomoni, Sandipan Dhar, Carsten Flohr, Dédée F. Murrell, Amy S. Paller, Emma Guttman‐Yassky	130
19	Differences in Disease-specific Quality of Life in Patients with Actinic Keratosis in Australia and Denmark. 2016 ·PubMed ·I.M. Miller, G.R. Vinding, Kian Zarchi, Solveig Esmann, Dédée F. Murrell, Gregor B. E. Jemec	5
20	Fibroblast-Derived Dermal Matrix Drives Development of Aggressive Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa 2012 ·Cancer Research ·(unknown), Céline Pourreyron, Julio C. Salas‐Alanís, Jasbani H.S. Dayal, Rodrigo Cepeda‐Valdes, (unknown), (unknown), Mei Chen, Jo‐David Fine, Fiona J. Hogg, John A. McGrath, Dédée F. Murrell, Irene M. Leigh, (unknown), Andrew P. South	103

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact